Latest News and Press Releases

STOUGHTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...

– Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 – – Non-GAAP Net Income of $31.2 Million in the First Quarter of 2020 – – Xtampza® ER Prescriptions Grew...

STOUGHTON, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...

STOUGHTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...

– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – – Conference Call Scheduled...

STOUGHTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...

– Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option – – Collegium will Host Conference Call to Discuss Fourth Quarter 2019 Financial...

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625%...

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000...

– Financially Transformative Acquisition – – Expected to Significantly Grow Net Income, EBITDA and Operating Cash Flows – – Structure of the Financing Allows for Rapid De-Leveraging – –...